Literature DB >> 20618396

Modeling new therapies for infantile spasms.

Lenka Chudomelova1, Morris H Scantlebury, Emmanuel Raffo, Antonietta Coppola, David Betancourth, Aristea S Galanopoulou.   

Abstract

Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies-high doses of adrenocorticotropic hormone, steroids, or the gamma-aminobutyric acid (GABA) transaminase inhibitor vigabatrin--are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20618396      PMCID: PMC2909007          DOI: 10.1111/j.1528-1167.2010.02605.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  A prospective study of infantile spasms: clinical and therapeutic correlations.

Authors:  C T Lombroso
Journal:  Epilepsia       Date:  1983-04       Impact factor: 5.864

2.  Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.

Authors:  C Chiron; C Dumas; I Jambaqué; J Mumford; O Dulac
Journal:  Epilepsy Res       Date:  1997-01       Impact factor: 3.045

3.  Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model.

Authors:  R Kábová; S Liptáková; R Slamberová; M Pometlová; L Velísek
Journal:  Epilepsia       Date:  1999-10       Impact factor: 5.864

4.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

Review 5.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

Review 6.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

7.  A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment.

Authors:  Maureen G Price; Jong W Yoo; Daniel L Burgess; Fang Deng; Richard A Hrachovy; James D Frost; Jeffrey L Noebels
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

8.  GABA(A) receptor properties in catastrophic infantile epilepsy.

Authors:  Laura A Jansen; Lindsey D Peugh; Jeffrey G Ojemann
Journal:  Epilepsy Res       Date:  2008-07-22       Impact factor: 3.045

9.  Go "West," young man...The quest for animal models of infantile spasms (West syndrome).

Authors:  Tallie Z Baram
Journal:  Epilepsy Curr       Date:  2007 Nov-Dec       Impact factor: 7.500

10.  Infantile spasms and Down syndrome: a new animal model.

Authors:  Miguel A Cortez; Liqing Shen; Ying Wu; Ilyas S Aleem; Catherine H Trepanier; Hamid R Sadeghnia; Asim Ashraf; Ashlin Kanawaty; Chen-Chu Liu; Lee Stewart; O Carter Snead
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

View more
  12 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

3.  Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms.

Authors:  Tomonori Ono; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2011-07-19       Impact factor: 5.864

Review 4.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

5.  Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms.

Authors:  Marine Jequier Gygax; Brian D Klein; H Steve White; Mimi Kim; Aristea S Galanopoulou
Journal:  Epilepsy Res       Date:  2013-10-28       Impact factor: 3.045

Review 6.  Latest American and European updates on infantile spasms.

Authors:  Andrew L Lux
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

Review 7.  Issues for new antiepilepsy drug development.

Authors:  Michele Simonato; Jacqueline A French; Aristea S Galanopoulou; Terence J O'Brien
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

Review 8.  Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.

Authors:  Anand Iyer; Richard Appleton
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

Review 9.  Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms.

Authors:  Pedro R Olivetti; Jeffrey L Noebels
Journal:  Curr Opin Neurobiol       Date:  2012-05-05       Impact factor: 6.627

Review 10.  Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.

Authors:  Aristea S Galanopoulou; Jan A Gorter; Carlos Cepeda
Journal:  Epilepsia       Date:  2012-05-11       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.